520 related articles for article (PubMed ID: 25024322)
1. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
[TBL] [Abstract][Full Text] [Related]
2. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
3. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
4. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.
Alcolea D; Vilaplana E; Pegueroles J; Montal V; Sánchez-Juan P; González-Suárez A; Pozueta A; Rodríguez-Rodríguez E; Bartrés-Faz D; Vidal-Piñeiro D; González-Ortiz S; Medrano S; Carmona-Iragui M; Sánchez-Saudinós M; Sala I; Anton-Aguirre S; Sampedro F; Morenas-Rodríguez E; Clarimón J; Blesa R; Lleó A; Fortea J
Neurobiol Aging; 2015 Jun; 36(6):2018-23. PubMed ID: 25865441
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
[TBL] [Abstract][Full Text] [Related]
8. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
[TBL] [Abstract][Full Text] [Related]
9. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
[TBL] [Abstract][Full Text] [Related]
10. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
14. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
15. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
Wallin AK; Blennow K; Andreasen N; Minthon L
Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
17. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
[TBL] [Abstract][Full Text] [Related]
19. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
Lleó A; Alcolea D; Martínez-Lage P; Scheltens P; Parnetti L; Poirier J; Simonsen AH; Verbeek MM; Rosa-Neto P; Slot RER; Tainta M; Izaguirre A; Reijs BLR; Farotti L; Tsolaki M; Vandenbergue R; Freund-Levi Y; Verhey FRJ; Clarimón J; Fortea J; Frolich L; Santana I; Molinuevo JL; Lehmann S; Visser PJ; Teunissen CE; Zetterberg H; Blennow K
Alzheimers Dement; 2019 Jun; 15(6):742-753. PubMed ID: 30967340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
